Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models

Hirokazu Suzuki(Daiichi Sankyo (Germany)), Toshinori Agatsuma(Daiichi Sankyo (Germany))

Molecular Cancer Therapeutics

January 10, 2024

10.1158/1535-7163.mct-23-0287

Cited by 29

Related Papers

Bystander killing effect of <scp>DS</scp>‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

|Cancer Science|2016|691

Novel Antibody Exerts Antitumor Effect through Downregulation of CD147 and Activation of Multiple Stress Signals

|Journal of Oncology|2022|7